AbbVie had a strong Q1 performance in its oncology, neuroscience, and immunology franchises. Read why I continue to rate ABBV ...

AbbVie raised its 2025 profit forecast on Friday after strong sales of its newer immunology drugs Skyrizi and Rinvoq helped ...

AbbVie Inc. beat revenue & EPS estimates, raised guidance due to Skyrizi & Rinvoq growth. Immunology shines; future ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...

Q1 2025 Management View CEO Rob Michael highlighted an excellent start to 2025, with adjusted EPS of $2.46, exceeding the guidance midpoint by $0.10, and total revenues surpassing $13.3 billion, ...

AbbVie Inc (ABBV) surpasses expectations with robust sales growth in Skyrizi and Rinvoq, while navigating challenges in ...

AbbVie stock climbs after Q1 earnings beat and 2025 EPS forecast raise; strong growth in immunology and neuroscience ...

For 2025, AbbVie forecast adjusted earnings per share at between $12.09 to $12.29, compared with earlier guidance in the range of $11.99 to $12.19. It noted that the current guidance is based on the ...

Cantor Fitzgerald starts AbbVie with an Overweight rating and $210 target, citing strong drug growth, low risk, and no major ...

Compounding the robust improvements in sales, AbbVie raised its profitability guidance for the full year. It now expects to post adjusted per-share earnings of $12.09 to $12.29; previously it was ...

In the Phase III SELECT-GCA trial, Rinvoq (upadacitinib) 15 mg with a 26-week glucocorticoid taper significantly improved ...

The decline was offset by sales of its newer arthritis drugs Skyrizi, which soared by 71% to $3.43 billion, and Rinvoq, which logged a 57% gain to $1.72 billion. Sales of its cosmetic botox ...